In plain terms

The claim being assessed: Persistent SARS-CoV-2 antigen or RNA in tissue reservoirs is a primary cause of post-acute COVID-19 symptoms.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: Overall Γ follows SC3. Human tissue associations and mechanistic models supply partial support, but primary clinical maintenance by persistent SARS-CoV-2 has not been identified. Antiviral nulls are important counterevidence to accessible replication, not evidence that every tissue reservoir was eliminated.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Viral persistence is a plausible Long-COVID contributor; evidence does not establish it as the generally primary symptom-maintaining cause.

Implications for health and treatment: Overall Γ follows SC3. Human tissue associations and mechanistic models supply partial support, but primary clinical maintenance by persistent SARS-CoV-2 has not been identified. Antiviral nulls are important counterevidence to accessible replication, not evidence that every tissue reservoir was eliminated.

Limits for individual care: 56 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 56 primary reports; claims: 60; verified: 60; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 53 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-10. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 3 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Viral persistence is a plausible Long-COVID contributor; evidence does not establish it as the generally primary symptom-maintaining cause.

Deciding experiment: Randomize a reservoir-directed intervention in a prespecified persistent-material phenotype, quantify relevant tissue target engagement before symptom change, and compare with matched placebo and infection-recovered controls.

Belief versus evidence: Overall Γ follows SC3. Human tissue associations and mechanistic models supply partial support, but primary clinical maintenance by persistent SARS-CoV-2 has not been identified. Antiviral nulls are important counterevidence to accessible replication, not evidence that every tissue reservoir was eliminated.

Best-supported rival: Heterogeneous post-infection maintenance pathways. Reservoir-clearance-verified intervention with temporal symptom/immune readouts would distinguish persistent-antigen dependence from self-sustaining injury or immune maintenance; current symptom-only antiviral nulls cannot do this alone.

COMPETING MECHANISTIC MODELS

Rank 1: Heterogeneous post-infection maintenance pathways (Γ). Immune, vascular, neural and tissue-injury pathways may contribute differently across phenotypes. Diverse biopsy, proteomic, exercise and antibody-transfer results support multiple candidate pathways. A flexible collection is not an established universal causal explanation.

Rank 2: Viral-reservoir primacy (Γ). Persistent viral material maintains most symptoms through continued immune signaling. Tissue RNA/antigen observations and viral-inflammatory model rescue support plausibility. Several established-disease antiviral trials have null primary results and no verified tissue-clearance demonstration.

Rank 3: Autonomous postinfectious immune maintenance (Γ). Immune pathology may persist after the initiating virus is cleared. Post-clearance mouse hyposmia perturbations and patient-IgG transfer support model pathways. Human pathway necessity and the proportion of patients explained remain unresolved.

Rank 4: Residual injury with impaired repair (Γ). Microvascular, muscle and small-fiber injuries may maintain selected functional deficits. Biopsy and provocation findings demonstrate local abnormalities. Observations do not identify the initiating cause or rule out ongoing antigen involvement.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Persistent SARS-CoV-2 antigen or RNA in tissue reservoirs is a primary cause of post-acute COVID-19 symptoms.

The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim.

Selection: remaining-priority list position 2 from the editorial list of 2026-10-09. No prior grade consulted; this is not independent blinded calibration.

Evidence and causal interpretation

Rubric fit: 05-immunology-inflammation governs viral-inflammatory persistence and its human symptom-maintenance inference. Direct model pathway perturbations remain valid in their tested model scopes, while the registered subclaims concern post-acute SARS-CoV-2 and human clinical primacy.

Persistence is real in selected human samples, but measurements identify different biological states. Autopsy RNA, circulating antigen, gut staining and focal dsRNA should not be collapsed into infectious-virus proof. In the PET study, selected symptomatic biopsies showed focal RNA while bulk PCR was negative; this assay discordance and the missing asymptomatic biopsy comparison limit causal conclusions. [25] [10] [56] [31]

The serotonin study provides an experimentally developed pathway. LCMV persistence and synthetic viral-RNA signaling reduced serotonin; sensing/interferon pathway interventions and vagal/serotonergic rescue changed model outcomes. This is stronger than correlation in those models, but selective removal of a SARS-CoV-2 reservoir in human Long COVID was not performed. [24]

STOP-PASC, PAXLC and RECOVER-VITAL did not improve their primary established-disease outcomes under the tested regimens. These results reduce confidence in broadly accessible ongoing replication as an easily reversible cause. They cannot establish clearance of compartmental reservoirs or nonreplicating antigen. Secondary STOP-PASC reports are one trial family. [12] [14] [16] [13] [17]

A small stopped acute-treatment trial reported less later Long COVID, but preventing injury during acute infection is not evidence that a reservoir maintains established symptoms. Alternative immune, muscle, vascular and neural pathways have partial evidence; transfer and post-clearance mouse perturbations are causal within their systems, not human syndrome-wide necessity. [15] [49] [5] [48] [39]

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Consensus consistency validation — 9 October 2026

Scope: retrospective validation of the archived v5.3 dossier, not a blind re-review. The preregistered scope remains persistent SARS-CoV-2 material as a primary cause maintaining symptoms in people meeting prospectively defined Long-COVID criteria; aggregation remains primary-subclaim SC3. Prior score: Γ, Moderate. Literature cutoff: 2026-10-09. Source records below were independently checked against PubMed primary reports on 2026-10-09 local (2026-10-10 UTC); this reconciles the archive's explicit UTC examination date.

Raw Consensus provenance

The parent's Consensus Pro response is preserved unchanged at consensus-browser-response.md, with raw thread record browser-thread.json. The direct Consensus keyword search results used in this check are also retained as source leads in that response's reference list. Do not treat the Consensus synthesis as original verified evidence or edit its citation markers.

Primary-source checks

Consensus-result reconciliation

Consensus usefully surfaced the Zuo cohort, STOP-PASC, PAX LC, and RECOVER-VITAL. Each already appears in the archived source inventory (Zuo PMID38663423; STOP-PASC PMID38848477; PAX LC PMID40188838; RECOVER-VITAL PMID42673984). The RECOVER-VITAL platform protocol is a protocol, not an outcome report, and is not counted as an independent trial. STOP-PASC secondary reports remain within the STOP-PASC trial family. The acute-treatment prevention study PMID42462744 remains outside the registered maintenance subclaim.

The raw Consensus answer overstates inference when it calls these trials "targeted antiviral eradication," describes a "clear dissociation between antiviral inhibition and clinical improvement," or says clinical intervention confirms that the virus does not independently maintain disease. Primary trial reports support no significant clinical benefit under the tested regimen and population. They do not show that tissue reservoirs were cleared or that tissue target engagement occurred. Preserve this as a claim-scope caveat; do not convert the nulls into proof of absence.

Per-subclaim score decision

• SC1 (presence after acute infection): Β, Moderate — unchanged. Tissue RNA/antigen presence is observed in selected human samples; the primary source checks corroborate the registered description.
• SC2 (viral material drives sustained immune/physiological disruption): Γ, Moderate — unchanged. The reviewed studies do not add a selective human reservoir perturbation or demonstrate a mechanistic clinical rescue.
• SC3 (primary cause of symptoms in clinically defined Long COVID): Γ, Moderate — unchanged. The four primary reports add no verified reservoir-removal intervention followed by symptom rescue; established-disease nulls are constraints on tested antiviral regimens, not direct clearance experiments.
• Aggregation remains primary-subclaim SC3: overall Γ, Moderate. No confidence-band change proposed: new validation confirms and sharpens source interpretation but does not resolve the causal gap or add independent positive causal lines. This is a retrospective consistency check, not blind calibration.

Sources

• Consensus raw response: consensus-browser-response.md; raw thread: browser-thread.json.
• PubMed: https://pubmed.ncbi.nlm.nih.gov/38663423/ ; https://pubmed.ncbi.nlm.nih.gov/38848477/ ; https://pubmed.ncbi.nlm.nih.gov/40188838/ ; https://pubmed.ncbi.nlm.nih.gov/42673984/

This dated supplement adds source reconciliation to the original review. Its original narrative, registered scope, source inventory and grades remain historical records. No earlier adversarial approval has been verified for this edition at the supplement date. This provenance supplement has no separate approval and is not an independent or blinded adjudication. New sources described here are supplemental and are not counted in the original inventory.

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Γ follows SC3. Human tissue associations and mechanistic models supply partial support, but primary clinical maintenance by persistent SARS-CoV-2 has not been identified. Antiviral nulls are important counterevidence to accessible replication, not evidence that every tissue reservoir was eliminated. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[5] Mouse post-infection hyposmia persisted after viral clearance and responded to senescence/immune-pathway perturbation. Model-specific maintenance without virus does not exclude reservoirs in other human phenotypes.

[12] STOP-PASC found no significant primary symptom benefit from a 15-day antiviral course. No verified clearance of the relevant tissue reservoir; null clinical benefit does not establish absence of all reservoirs. An erratum is attached.

[14] PAXLC found no significant primary physical-health benefit from the tested antiviral course. The intervention may not eradicate compartmental or nonreplicating antigen; this is not a verified reservoir-removal experiment.

[15] A small prematurely stopped acute-treatment trial reported less subsequent Long COVID. Prevention after acute infection does not demonstrate maintenance by a reservoir in established disease.

[16] RECOVER-VITAL found no significant primary benefits for the tested established-Long-COVID symptom phenotypes. Late antiviral nulls constrain treatment-responsive replication, but do not document reservoir clearance in tissues.

[24] Human metabolomics and mouse interventions linked viral-inflammatory signaling to serotonin/vagal-memory changes. LCMV persistence, poly(I:C), receptor manipulation and rescue are model evidence, not selective SARS-CoV-2 reservoir removal in humans.

[49] Transfer of patient IgG caused selected fatigue/pain/nerve phenotypes in mice. Passive transfer supports model pathogenic potential, not endogenous human necessity or a single cause across Long COVID.

Tally: 7 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. The tally counts reports with discriminating intervention contrasts, including negative results; it is not a count of positive causal crossings. Shared parent trials and multiple manipulations within a study remain grouped.

Cap audit, precedence and Β/Γ/Δ boundary

A conditional immune manipulation can cross a model threshold without crossing the full human reservoir-primacy claim. Clinical antiviral perturbation counts as a discriminator, but a null result neither crosses Δ positively nor proves absence of a reservoir without engagement evidence.

Universal six-cap audit: 1: In vitro evidence alone cannot exceed Γ; cell and biochemical findings do not establish human endogenous causality. 2: Pure association evidence cannot exceed Β; association-only presence/risk/reliability subclaims retain Β. 3: Overexpression in model systems caps at Γ for the broader claim; artificially engaged targets are not endogenous human necessity. 4: Biomarker change without functional/phenotypic change caps at Γ; clocks, concentrations and immune markers cannot replace functional outcomes. 5: Seeding or forced-transfer paradigms cap at Γ for endogenous propagation claims; injected spike, transferred IgG and forced model stimulation retain their model scope. 6: Familial/syndromic genetic findings remain scope-restricted; ALS/syndromic model mechanisms do not automatically establish general aging or sporadic human disease. None of these is reapplied to downgrade a genuinely convergent same-scope causal set.

Gamma hard-rule audit: Human associations and biomarker-only changes do not establish the broad causal claim. Model perturbations bind their tested species and phenotype, not an untested human scope. Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification.

SC1 cap: “Pure association evidence — however large, however replicated — cannot exceed Β.” RNA and antigen persistence are directly observed in selected human samples, with symptom associations. These presence findings are not by themselves a causal proposition or infectious-virus recovery.

SC1 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. RNA and antigen persistence are directly observed in selected human samples, with symptom associations. These presence findings are not by themselves a causal proposition or infectious-virus recovery.

SC2 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. Viral-inflammatory signaling has model perturbation/rescue support and human correlates, but the exact persistent-SARS-CoV-2-to-human-syndrome link remains incompletely tested.

SC3 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. No selected study verifies relevant reservoir removal followed by specific, substantial rescue of established human Long COVID. Multiple antiviral primary nulls constrain a broadly treatment-responsive replication model without proving reservoir eradication.

Upward threshold ladder

SC1 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Presence must be connected to a pathway-specific causal perturbation rather than counted as a mechanistic crossing.

SC2 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Selective relevant reservoir or sensing-pathway perturbation must change the stated post-acute disease phenotype with model-to-human alignment.

SC3 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Document tissue target engagement/clearance before a prespecified clinically meaningful symptom response, contrasted with matched controls.

Upper ladder: No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately.

Independence: Different publications, laboratories and agents do not automatically form independent causal lines. No nominal Ζ or higher is assigned.

Falsification and pitfalls

RNA versus replication. PCR, antigen and focal dsRNA signals do not all establish recoverable infectious virus.

Target engagement. Antiviral nulls lack verified eradication of the symptom-relevant tissue reservoir.

Ectopic model generalization. Injected spike and poly(I:C) do not reproduce every endogenous human persistence mechanism.

Adversarial steelman: above, then below

Case for Δ: tissue viral material coexists with prolonged immune activation; mouse sensing-pathway interventions and rescue demonstrate causal biology, and acute antiviral prevention can improve later outcomes. The missing step is a positive, target-engaged intervention on the registered established-human-disease maintenance claim.

Case for Β: human reservoir data are largely observational and several late antiviral trials are null. Model pathway/rescue support and prospective infection biology nevertheless exceed association alone; the nulls did not prove tissue clearance.

Reject Δ for missing positive full-scope perturbation and Β because experimentally supported partial mechanisms remain. Retain Γ without reclassifying an acute-prevention result as late maintenance proof.

Final score, causal direction and M/S/D

Overall Γ follows SC3. Human tissue associations and mechanistic models supply partial support, but primary clinical maintenance by persistent SARS-CoV-2 has not been identified. Antiviral nulls are important counterevidence to accessible replication, not evidence that every tissue reservoir was eliminated.

At the registered human-primary-maintenance scope, neither reservoir necessity nor a reverse dependency is demonstrated. Step 2 records unresolved causal dependency for this claim, not a finding that persistent antigen is inert. Model inflammatory signaling has causal effects in narrower systems, which do not establish the role of the human reservoir.

Momentum: Mechanistic only. STOP-PASC, PAXLC and RECOVER-VITAL (PMIDs 38848477, 40188838, 42673984) are completed clinical perturbations but lack verified reservoir eradication. Recent tissue and model work (PMIDs 41794369, 41963730) continues mechanism exploration; no verified pending clearance-to-rescue result was identified.

Stability: Stable. No specific pending result with a verified completion trigger was identified in this bounded search; Stable follows the framework definition, not a forecast of permanent truth.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Randomize a reservoir-directed intervention in a prespecified persistent-material phenotype, quantify relevant tissue target engagement before symptom change, and compare with matched placebo and infection-recovered controls.

Readout: Longitudinal tissue viral material/replication assays, immune mediators and prespecified functional symptom trajectories. Controls: Blinding integrity, relevant compartment sampling, reinfection monitoring and unchanged supportive treatment. Supporting: Verified specific reservoir reduction precedes clinically meaningful improvement and predicted immune normalization. Falsifying: Verified adequate relevant-reservoir clearance leaves the predicted symptoms unchanged over the registered horizon.

KNOWLEDGE GAPS

Which compartments contain biologically active versus residual viral material?

How often does persistence occur in symptom-matched recovered controls?

Which symptom phenotypes depend on continued antigen rather than autonomous injury?

Clinical reservoir engagement was not demonstrated in the selected late antiviral trials.

REVIEWER NOTES

Fifty to seventy original primary reports were selected before adjudication. Exact bounded abstract passages and selected body paragraphs are retained with examination receipts. Most papers were not read in full; absent details are limitations, not assumed controls. No independent blind grading, Consensus, Scite or independent scientific peer review was performed for the original review; the dated 9 October 2026 Consensus consistency validation above is a later provenance supplement and is not an independent blinded adjudication. Popularity is editorial interest, not measured demand. The preregistered wording uses antigen or RNA as alternative measurements within one parent viral-material-reservoir claim. They are not treated as equivalent replication states; presence is decomposed from immune effects and clinical primacy. The validator disjunction warning is retained and resolved by this parent/subclaim decomposition rather than silently changing the registered hypothesis. Models are a descriptive tournament; their rankings are not independent causal proof. Grades were derived from selected primary evidence after claim registration, without consulting a previous completed grade. The primary-subclaim aggregation is fixed; weakest-link sensitivities remain displayed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14. This edition is the revised copy produced by the 2026-10-09 Consensus-consistency audit; it was reviewed as it now stands, and every number in the block the revision added was re-derived from the records it cites.

Scope of checks. REFERENCE PMIDs verified against PubMed metadata: 56/56 resolve to the stated title, first author, journal and year; DOIs cross-checked for all 56; no reference carries a retraction, retraction-of-publication or expression-of-concern flag; no reference has a dropped collective author, a stray leading comma or an empty DOI field. Load-bearing claims spot-checked against PubMed abstracts: 10 (the tissue-persistence cohort's sample base, its 4-month questionnaire and its symptom association; STOP-PASC's design, size, primary endpoint and null result; PAX LC's enrolment and day-28 estimate; RECOVER-VITAL's enrolment, phenotypes, regimens and per-phenotype primary estimates; the acute-treatment prevention trial's scope; the IgG passive-transfer result; and the serotonin/viral-inflammatory model pathway). Scoring logic re-derived against references/hsef-framework.md and rubric 05-immunology-inflammation: ladder letter and canonical descriptor, the six universal caps, the pre-registered primary-subclaim aggregation with SC3 named, the causal-role derivation, and the momentum artifact.

Findings.

No level, confidence, role, momentum, stability or divergence value was changed. Final score remains Γ — Mechanistically plausible, partial system support; confidence Moderate; role epiphenomenon.

Verification of the block the revision added. Every quantitative claim in the 2026-10-09 supplement is correct against the primary records: the tissue cohort's 225 patients, its residual clinical specimens, its 4-month telephone questionnaire and its association (odds ratio 5.17, 95% CI 2.64-10.13), together with the authors' own statement that further work is needed to verify a mechanistic link; STOP-PASC's 155 participants, 15-week blinded placebo-controlled design, pooled six-symptom primary endpoint at week 10 and null result in a nearly fully vaccinated cohort; PAX LC's phase 2 design, 100 enrolled participants and day-28 PROMIS-29 physical-health difference of -0.55 (95% CI -2.32 to 1.21, p = 0.54) under NCT05668091; and RECOVER-VITAL's 959 mITT participants across cognitive, autonomic and exercise phenotypes with no statistically significant primary benefit for any phenotype under either the 15-day or the 25-day regimen, under NCT05595369. The block's refusal to convert those nulls into proof of reservoir absence, and its insistence that target engagement was not demonstrated, are both correct and are the framework-faithful reading. No substantive regression was introduced by the revision.

Rejected findings (checked, no change).

1. Aggregation. Pre-registered rule is primary-subclaim with SC3 named; the headline equals SC3 (Γ). Reported alternatives are correct: weakest-link is min(Β, Γ, Γ) = Β, and scope-matched is Γ because SC3 is the only subclaim scoped to people meeting prospectively defined Long-COVID criteria. No change.
2. Causal role. "Epiphenomenon" is derived at step 2 and the derivation paragraph states exactly that, while explicitly not claiming persistent antigen is inert. No change.
3. Momentum. "Mechanistic only" names its artifact (three completed antiviral trials that lack verified reservoir eradication, plus continuing tissue and model work) and correctly declines "Decisive work underway", since no pending clearance-to-rescue result was identified. No change.
4. Causal-tally count. The tally states 7 discriminating contrasts and the inventory prints exactly 7 bracketed items; the score card agrees. No change.
5. v5.claim_form disjunction warning. The registered wording uses "antigen or RNA" as alternative measurements of one parent reservoir claim and the review decomposes presence from immune effects and clinical primacy rather than silently rewriting the hypothesis. Rejected per the registered convention, as the review itself records.
6. Validator lay-summary failure. The v5.4 framework copies in this package add a mandatory v5.lay_summary check; this review is v5.3 and the version stored with the case returns ok, so the failure is a validator-version artifact. No lay summary was added.
7. Score-card review_metadata.reviewer reads "Codex". This string is identical across every score card in this corpus, so it is house provenance rather than a defect in this review, and renaming it is not a single-case edit. Flagged for the lead rather than changed.

Residual limitations. Only 3 of 56 reports were examined at partial-body depth. Two statements could not be re-derived from the records consulted here: RECOVER-VITAL's "no secondary endpoint differences" (the abstract names the secondary measures without reporting all of them) and the claim that the raw Consensus file misassigns a PMID to the STOP-PASC DOI, which depends on the archived provider file rather than on a primary record.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. -- Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Vogelgesang A, Steinmetz A, Stufano A et al. Anti-neuronal and anti-mitochondrial autoantibodies are associated with lower functional status and more severe respiratory symptoms in post COVID syndrome. Frontiers in immunology. 2025. PMID 40995367. DOI: 10.3389/fimmu.2025.1642250. Access: abstract_metadata. Study: PMID40995367.

2. Bussani R, Zentilin L, Correa R et al. Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19. The Journal of pathology. 2023. PMID 36651103. DOI: 10.1002/path.6035. Access: abstract_metadata. Study: PMID36651103.

3. Yoon GY, Chung YC, Choi JH et al. SARS-CoV-2 infection is associated with hypothalamic orexin suppression and persistent cortical NeuN attenuation. Journal of neuroinflammation. 2026. PMID 42087199. DOI: 10.1186/s12974-026-03842-y. Access: abstract_metadata. Study: PMID42087199.

4. Ravkov EV, Williams ESCP, Elgort M et al. Reduced monocyte proportions and responsiveness in convalescent COVID-19 patients. Frontiers in immunology. 2023. PMID 38250080. DOI: 10.3389/fimmu.2023.1329026. Access: abstract_metadata. Study: PMID38250080.

5. Tsuji S, Nakano S, Ito K et al. Senescence-like cells recruit γδ T cells to drive prolonged hyposmia after SARS-CoV-2 infection in mice. EMBO reports. 2026. PMID 41963730. DOI: 10.1038/s44319-026-00769-6. Access: abstract_metadata. Study: PMID41963730.

6. Montes-Cobos E, Bastos VC, Monteiro C et al. Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies. iScience. 2023. PMID 37529320. DOI: 10.1016/j.isci.2023.107219. Access: abstract_metadata. Study: PMID37529320.

7. Hejbøl EK, Harbo T, Agergaard J et al. Myopathy as a cause of fatigue in long-term post-COVID-19 symptoms: Evidence of skeletal muscle histopathology. European journal of neurology. 2022. PMID 35661354. DOI: 10.1111/ene.15435. Access: abstract_metadata. Study: PMID35661354.

8. Korobova ZR, Arsentieva NA, Butenko AA et al. T Cell Dynamics in COVID-19, Long COVID and Successful Recovery. International journal of molecular sciences. 2025. PMID 40806391. DOI: 10.3390/ijms26157258. Access: abstract_metadata. Study: PMID40806391.

9. Augustin M, Picard L, Rauschning D et al. Persistent Gut-Immune Axis dysregulation in long-term Post-COVID Syndrome: Insights from a prospective, observational, cross-sectional case-control study. Mucosal immunology. 2026. PMID 41794369. DOI: 10.1016/j.mucimm.2026.03.002. Access: abstract_metadata. Study: PMID41794369.

10. Cherne MD, Gentry AB, Nemudraia A et al. Severe Acute Respiratory Syndrome Coronavirus 2 Is Detected in the Gastrointestinal Tract of Asymptomatic Endoscopy Patients but Is Unlikely to Pose a Significant Risk to Healthcare Personnel. Gastro hep advances. 2022. PMID 35765598. DOI: 10.1016/j.gastha.2022.06.002. Access: abstract_metadata. Study: PMID35765598.

11. Hany M, Sheta E, Talha A et al. Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination. Endoscopy international open. 2024. PMID 38188925. DOI: 10.1055/a-2180-9872. Access: abstract_metadata. Study: PMID38188925.

12. Geng LN, Bonilla H, Hedlin H et al. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA internal medicine. 2024. PMID 38848477. DOI: 10.1001/jamainternmed.2024.2007. Access: full_text_partial. Study: STOP_PASC.

13. Gunturkun F, Hedlin H, Botzheim B et al. Digital Biometric Measures in Long COVID: A Secondary Analysis of the STOP-PASC Randomized Clinical Trial. JAMA network open. 2025. PMID 40810942. DOI: 10.1001/jamanetworkopen.2025.26901. Access: abstract_metadata. Study: STOP_PASC.

14. Sawano M, Bhattacharjee B, Caraballo C et al. Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial. The Lancet. Infectious diseases. 2025. PMID 40188838. DOI: 10.1016/S1473-3099(25)00073-8. Access: abstract_metadata. Study: NCT05668091.

15. Oppegaard O, Blomberg B, Cox RJ et al. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial. The Lancet. Infectious diseases. 2026. PMID 42462744. DOI: 10.1016/S1473-3099(26)00244-6. Access: abstract_metadata. Study: NCT05852873.

16. Baden LR, Shah NS, Liu STH et al. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Infectious diseases. 2026. PMID 42673984. DOI: 10.1016/S1473-3099(26)00406-8. Access: abstract_metadata. Study: NCT05595369.

17. Jagannathan P, Hedlin H, Liang JW et al. Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial. Open forum infectious diseases. 2025. PMID 41164784. DOI: 10.1093/ofid/ofaf634. Access: abstract_metadata. Study: STOP_PASC.

18. Wang E, Patel ZM. Paxlovid Is Associated With Lower Rates of Long COVID-19 Smell and Taste Disorders. International forum of allergy & rhinology. 2025. PMID 40444408. DOI: 10.1002/alr.23612. Access: abstract_metadata. Study: PMID40444408.

19. Evering TH, Moser CB, Jilg N et al. Long COVID After Bamlanivimab Treatment. The Journal of infectious diseases. 2023. PMID 37650236. DOI: 10.1093/infdis/jiad286. Access: abstract_metadata. Study: NCT04518410.

20. Saito S, Shahbaz S, Osman M et al. Diverse immunological dysregulation, chronic inflammation, and impaired erythropoiesis in long COVID patients with chronic fatigue syndrome. Journal of autoimmunity. 2024. PMID 38797051. DOI: 10.1016/j.jaut.2024.103267. Access: abstract_metadata. Study: PMID38797051.

21. Turner S, Naidoo CA, Usher TJ et al. Increased Levels of Inflammatory and Endothelial Biomarkers in Blood of Long COVID Patients Point to Thrombotic Endothelialitis. Seminars in thrombosis and hemostasis. 2024. PMID 37207671. DOI: 10.1055/s-0043-1769014. Access: abstract_metadata. Study: PMID37207671.

22. Sommen SL, Segtnan S, Selvakumar J et al. Long COVID: Deep single-cell immunophenotyping and machine learning reveal a general signature for fatigue. Journal of translational medicine. 2026. PMID 42021271. DOI: 10.1186/s12967-026-08149-3. Access: abstract_metadata. Study: PMID42021271.

23. Hellmuth J, Barnett TA, Asken BM et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. Journal of neurovirology. 2021. PMID 33528824. DOI: 10.1007/s13365-021-00954-4. Access: abstract_metadata. Study: PMID33528824.

24. Wong AC, Devason AS, Umana IC et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023. PMID 37848036. DOI: 10.1016/j.cell.2023.09.013. Access: full_text_partial. Study: PMID37848036.

25. Stein SR, Ramelli SC, Grazioli A et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022. PMID 36517603. DOI: 10.1038/s41586-022-05542-y. Access: abstract_metadata. Study: PMID36517603.

26. Nayyerabadi M, Fourcade L, Joshi SA et al. Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2023. PMID 37717649. DOI: 10.1016/j.ijid.2023.09.006. Access: abstract_metadata. Study: PMID37717649.

27. Peter RS, Nieters A, Göpel S et al. Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study. PLoS medicine. 2025. PMID 39847575. DOI: 10.1371/journal.pmed.1004511. Access: abstract_metadata. Study: PMID39847575.

28. Su Y, Yuan D, Chen DG et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022. PMID 35216672. DOI: 10.1016/j.cell.2022.01.014. Access: abstract_metadata. Study: PMID35216672.

29. Klein J, Wood J, Jaycox JR et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023. PMID 37748514. DOI: 10.1038/s41586-023-06651-y. Access: abstract_metadata. Study: PMID37748514.

30. Rong Z, Mai H, Ebert G et al. Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19. Cell host & microbe. 2024. PMID 39615487. DOI: 10.1016/j.chom.2024.11.007. Access: abstract_metadata. Study: PMID39615487.

31. Peluso MJ, Ryder D, Flavell RR et al. Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection. Science translational medicine. 2024. PMID 38959327. DOI: 10.1126/scitranslmed.adk3295. Access: full_text_partial. Study: PMID38959327.

32. Thierry AR, Usher T, Sanchez C et al. Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients. Journal of medical virology. 2025. PMID 41036702. DOI: 10.1002/jmv.70613. Access: abstract_metadata. Study: PMID41036702.

33. Shahbaz S, Rezaeifar M, Syed H et al. Upregulation of olfactory receptors and neuronal-associated genes highlights complex immune and neuronal dysregulation in Long COVID patients. Brain, behavior, and immunity. 2025. PMID 39615603. DOI: 10.1016/j.bbi.2024.11.032. Access: abstract_metadata. Study: PMID39615603.

34. Pisareva E, Badiou S, Mihalovičová L et al. Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients. Journal of medical virology. 2023. PMID 36226380. DOI: 10.1002/jmv.28209. Access: abstract_metadata. Study: PMID36226380.

35. Hamlin RE, Pienkos SM, Chan L et al. Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution. Science translational medicine. 2024. PMID 39536117. DOI: 10.1126/scitranslmed.adr1032. Access: abstract_metadata. Study: PMID39536117.

36. Thurner L, Fadle N, Regitz E et al. Autoantibodies against SUMO1-DHX35 in long-COVID. Journal of translational autoimmunity. 2022. PMID 36425003. DOI: 10.1016/j.jtauto.2022.100171. Access: abstract_metadata. Study: PMID36425003.

37. Apostolou E, Rizwan M, Moustardas P et al. Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome. Frontiers in immunology. 2022. PMID 36341457. DOI: 10.3389/fimmu.2022.949787. Access: abstract_metadata. Study: PMID36341457.

38. Zuo W, He D, Liang C et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. The Lancet. Infectious diseases. 2024. PMID 38663423. DOI: 10.1016/S1473-3099(24)00171-3. Access: abstract_metadata. Study: PMID38663423.

39. Cervia-Hasler C, Brüningk SC, Hoch T et al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science (New York, N.Y.). 2024. PMID 38236961. DOI: 10.1126/science.adg7942. Access: abstract_metadata. Study: PMID38236961.

40. Yin K, Peluso MJ, Luo X et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nature immunology. 2024. PMID 38212464. DOI: 10.1038/s41590-023-01724-6. Access: abstract_metadata. Study: PMID38212464.

41. Aid M, Boero-Teyssier V, McMahan K et al. Long COVID involves activation of proinflammatory and immune exhaustion pathways. Nature immunology. 2026. PMID 41388153. DOI: 10.1038/s41590-025-02353-x. Access: abstract_metadata. Study: PMID41388153.

42. Mak WA, Wapperom D, Redel AL et al. Seasonal Coronavirus-Induced Immunological Imprinting and Previous Herpesvirus Infections in Patients With Long COVID. Journal of medical virology. 2025. PMID 40884088. DOI: 10.1002/jmv.70582. Access: abstract_metadata. Study: PMID40884088.

43. Hai Z, Yang W, Ghazi A et al. Increased anti-nucleocapsid secretory IgA and consumption of complement component 3 in post-COVID syndrome patients. Frontiers in immunology. 2026. PMID 42220539. DOI: 10.3389/fimmu.2026.1822171. Access: abstract_metadata. Study: PMID42220539.

44. Acosta-Ampudia Y, Monsalve DM, Rojas M et al. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. The Journal of infectious diseases. 2022. PMID 35079804. DOI: 10.1093/infdis/jiac017. Access: abstract_metadata. Study: PMID35079804.

45. Drobinska N, Nehme M, Assal F et al. Small Fiber Neuropathy in Long COVID: A Cohort Study with Multimodal Assessment and Follow-Up. European neurology. 2025. PMID 40460818. DOI: 10.1159/000546015. Access: abstract_metadata. Study: PMID40460818.

46. Schmitz B, Garbsch R, Schäfer H et al. Autonomic dysfunction and vasoregulation in long COVID-19 are linked to anti-GPCR autoantibodies. The Journal of allergy and clinical immunology. 2026. PMID 41274384. DOI: 10.1016/j.jaci.2025.10.034. Access: abstract_metadata. Study: PMID41274384.

47. Aschman T, Wyler E, Baum O et al. Post-COVID exercise intolerance is associated with capillary alterations and immune dysregulations in skeletal muscles. Acta neuropathologica communications. 2023. PMID 38066589. DOI: 10.1186/s40478-023-01662-2. Access: abstract_metadata. Study: PMID38066589.

48. Appelman B, Charlton BT, Goulding RP et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature communications. 2024. PMID 38177128. DOI: 10.1038/s41467-023-44432-3. Access: abstract_metadata. Study: NCT05225688.

49. de Sá KSG, Silva J, Bayarri-Olmos R et al. A causal link between autoantibodies and neurological symptoms in long COVID. Cell. 2026. PMID 42208499. DOI: 10.1016/j.cell.2026.04.042. Access: abstract_metadata. Study: PMID42208499.

50. Rojas M, Rodríguez Y, Acosta-Ampudia Y et al. Autoimmunity is a hallmark of post-COVID syndrome. Journal of translational medicine. 2022. PMID 35296346. DOI: 10.1186/s12967-022-03328-4. Access: abstract_metadata. Study: PMID35296346.

51. Schultheiß C, Willscher E, Paschold L et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell reports. Medicine. 2022. PMID 35732153. DOI: 10.1016/j.xcrm.2022.100663. Access: abstract_metadata. Study: PMID35732153.

52. Son K, Jamil R, Chowdhury A et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. The European respiratory journal. 2023. PMID 36137590. DOI: 10.1183/13993003.00970-2022. Access: abstract_metadata. Study: PMID36137590.

53. Hofmann S, Lucio M, Wallukat G et al. Functional Autoantibodies Targeting G-Protein-Coupled Receptors and Their Clinical Phenotype in Patients with Long-COVID. International journal of molecular sciences. 2025. PMID 40724994. DOI: 10.3390/ijms26146746. Access: abstract_metadata. Study: PMID40724994.

54. Fracella M, Mancino E, Nenna R et al. Age-related transcript changes in type I interferon signaling in children and adolescents with long COVID. European journal of immunology. 2024. PMID 38522030. DOI: 10.1002/eji.202350682. Access: abstract_metadata. Study: PMID38522030.

55. Pienkos S, Swank Z, Hamlin RE et al. Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients. Open forum infectious diseases. 2025. PMID 40926879. DOI: 10.1093/ofid/ofaf515. Access: abstract_metadata. Study: PMID40926879.

56. Swank Z, Senussi Y, Manickas-Hill Z et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023. PMID 36052466. DOI: 10.1093/cid/ciac722. Access: abstract_metadata. Study: PMID36052466.

Source-specific evidence cards

[1] Anti-neuronal and anti-mitochondrial autoantibodies are associated with lower functional status and more severe respiratory symptoms in post COVID syndrome.

Shows: Autoantibody profiles predicted selected post-COVID functional and respiratory outcomes.

Does not show: Prediction does not establish antibody necessity or viral primacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[2] Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19.

Shows: Fatal-case autopsies detected SARS-CoV-2 RNA in selected tissues despite negative nasal tests.

Does not show: Severe fatal cases are not representative Long COVID, and RNA does not alone establish infectious replication.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[3] SARS-CoV-2 infection is associated with hypothalamic orexin suppression and persistent cortical NeuN attenuation.

Shows: Infected mice showed persistent viral RNA and neuronal changes; orexin intervention affected neuronal markers.

Does not show: Transgenic models and marker rescue do not establish human symptom rescue after reservoir clearance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[4] Reduced monocyte proportions and responsiveness in convalescent COVID-19 patients.

Shows: Convalescent monocytes showed altered functions in ex vivo assays.

Does not show: Ex vivo dysfunction is not Long-COVID-specific or in vivo causal dependency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID37961575. Subclaims: SC1, SC2, SC3.

[5] Senescence-like cells recruit γδ T cells to drive prolonged hyposmia after SARS-CoV-2 infection in mice.

Shows: Mouse post-infection hyposmia persisted after viral clearance and responded to senescence/immune-pathway perturbation.

Does not show: Model-specific maintenance without virus does not exclude reservoirs in other human phenotypes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[6] Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies.

Shows: Oligosymptomatic long-term carriers had altered immune profiles.

Does not show: Persistence with few symptoms challenges simple sufficiency but does not prove a complete negative control for all tissues.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[7] Myopathy as a cause of fatigue in long-term post-COVID-19 symptoms: Evidence of skeletal muscle histopathology.

Shows: Long-COVID muscle biopsies showed inflammatory, mitochondrial and microvascular abnormalities.

Does not show: Small selected biopsies without reservoir manipulation cannot establish the initiating mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[8] T Cell Dynamics in COVID-19, Long COVID and Successful Recovery.

Shows: Long-COVID immune profiles included altered T-cell and Th2 patterns.

Does not show: Cell-state associations do not identify causal direction or antigen dependence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[9] Persistent Gut-Immune Axis dysregulation in long-term Post-COVID Syndrome: Insights from a prospective, observational, cross-sectional case-control study.

Shows: Post-COVID ileal viral protein was associated with local immune and barrier abnormalities.

Does not show: Observational biopsy selection and protein detection do not prove replication or symptom causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[10] Severe Acute Respiratory Syndrome Coronavirus 2 Is Detected in the Gastrointestinal Tract of Asymptomatic Endoscopy Patients but Is Unlikely to Pose a Significant Risk to Healthcare Personnel.

Shows: Endoscopy samples contained viral material after infection without recoverable infectious virus.

Does not show: Material persistence and infectious replication must remain distinct; the study did not remove the reservoir.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[11] Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination.

Shows: Gut immunostaining showed persistent viral protein with regional and clinical differences.

Does not show: Absence of clear symptom differences prevents inferring that detection alone explains symptoms.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[12] Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial.

Shows: STOP-PASC found no significant primary symptom benefit from a 15-day antiviral course.

Does not show: No verified clearance of the relevant tissue reservoir; null clinical benefit does not establish absence of all reservoirs. An erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph8, 2:Results:paragraph17. No complete-paper or supplement audit claimed. ErratumIn: PMID39037781. Subclaims: SC1, SC2, SC3.

[13] Digital Biometric Measures in Long COVID: A Secondary Analysis of the STOP-PASC Randomized Clinical Trial.

Shows: STOP-PASC wearable analyses did not show a clear intervention benefit.

Does not show: Secondary analysis with attrition, same trial family and no tissue-clearance endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[14] Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.

Shows: PAXLC found no significant primary physical-health benefit from the tested antiviral course.

Does not show: The intervention may not eradicate compartmental or nonreplicating antigen; this is not a verified reservoir-removal experiment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[15] Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.

Shows: A small prematurely stopped acute-treatment trial reported less subsequent Long COVID.

Does not show: Prevention after acute infection does not demonstrate maintenance by a reservoir in established disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[16] Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

Shows: RECOVER-VITAL found no significant primary benefits for the tested established-Long-COVID symptom phenotypes.

Does not show: Late antiviral nulls constrain treatment-responsive replication, but do not document reservoir clearance in tissues.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[17] Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial.

Shows: STOP-PASC trajectories did not identify a clear broadly responsive symptom subgroup.

Does not show: Same randomized cohort; exploratory trajectories are not independent tests of reservoir removal.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[18] Paxlovid Is Associated With Lower Rates of Long COVID-19 Smell and Taste Disorders.

Shows: Early antiviral treatment was associated with fewer later smell/taste problems.

Does not show: Observational treatment selection and acute timing do not establish late symptom mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[19] Long COVID After Bamlanivimab Treatment.

Shows: A bamlanivimab-treated cohort developed persistent symptoms without a clear nasal-RNA association.

Does not show: Nasal sampling is not tissue clearance and cohort analysis is not a randomized late reservoir intervention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[20] Diverse immunological dysregulation, chronic inflammation, and impaired erythropoiesis in long COVID patients with chronic fatigue syndrome.

Shows: Long-COVID and ME/CFS cohorts showed immune dysregulation.

Does not show: Shared phenotype signatures do not identify a unique viral cause.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[21] Increased Levels of Inflammatory and Endothelial Biomarkers in Blood of Long COVID Patients Point to Thrombotic Endothelialitis.

Shows: Endothelial and blood markers supported vascular involvement in Long COVID.

Does not show: Associations do not establish microclots as the primary driver or prove independence from inflammation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[22] Long COVID: Deep single-cell immunophenotyping and machine learning reveal a general signature for fatigue.

Shows: Fatigued post-COVID and other fatigued participants shared immune features.

Does not show: Nonspecific signatures constrain diagnostic specificity but not every causal pathway.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[23] Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients.

Shows: An outpatient cohort documented prolonged neurological and cognitive symptoms.

Does not show: Natural history establishes burden, not viral causality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[24] Serotonin reduction in post-acute sequelae of viral infection.

Shows: Human metabolomics and mouse interventions linked viral-inflammatory signaling to serotonin/vagal-memory changes.

Does not show: LCMV persistence, poly(I:C), receptor manipulation and rescue are model evidence, not selective SARS-CoV-2 reservoir removal in humans.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:RESULTS:paragraph4, 1:RESULTS:paragraph5, 1:RESULTS:paragraph19. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[25] SARS-CoV-2 infection and persistence in the human body and brain at autopsy.

Shows: Autopsy work detected long-lasting SARS-CoV-2 RNA in multiple organs.

Does not show: Predominantly severe/fatal disease and limited local injury do not establish a dominant cause of typical Long COVID.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[26] Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses.

Shows: An observational vaccination study reported symptom changes alongside persistent antigen findings.

Does not show: Vaccination has multiple effects and was not randomized selective reservoir clearance; an erratum is attached.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID39983460. Subclaims: SC1, SC2, SC3.

[27] Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.

Shows: Population follow-up documented heterogeneous persistence and reinfection-related trajectories.

Does not show: Phenotype trajectories do not identify a common reservoir mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[28] Multiple early factors anticipate post-acute COVID-19 sequelae.

Shows: Early RNAemia, autoantibodies, EBV signals and diabetes predicted later sequelae.

Does not show: Temporal predictors can mark acute severity or susceptibility without being the maintenance mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[29] Distinguishing features of long COVID identified through immune profiling.

Shows: Long-COVID immune profiling identified cortisol and antiviral immune differences.

Does not show: Cross-sectional profiles are not targeted mediator perturbation; an updated preprint is not a separate source.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID35982667. Subclaims: SC1, SC2, SC3.

[30] Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19.

Shows: Human brain-border spike findings and mouse spike exposure supported a possible neuroimmune pathway.

Does not show: Exogenous spike administration is not endogenous human reservoir necessity or sufficient explanation of the syndrome.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[31] Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection.

Shows: PET revealed prolonged tissue T-cell activation; selected gut biopsies contained focal viral RNA signals.

Does not show: All five biopsied participants were symptomatic; absent asymptomatic biopsy controls and negative bulk PCR restrict causal interpretation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:RESULTS:paragraph14, 1:RESULTS:paragraph15, 1:RESULTS:paragraph16. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[32] Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients.

Shows: Structural analyses associated microclot/NET features with Long COVID.

Does not show: Structural presence does not establish necessity, sufficiency or upstream timing.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[33] Upregulation of olfactory receptors and neuronal-associated genes highlights complex immune and neuronal dysregulation in Long COVID patients.

Shows: Transcriptomic profiling linked Long-COVID/ME-CFS phenotypes to immune and neural pathways.

Does not show: Expression patterns and potentially related recruitment do not establish an independent causal mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[34] Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients.

Shows: Post-acute samples showed NET-associated marker changes.

Does not show: Markers do not establish that NET blockade changes clinical disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[35] Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution.

Shows: Longitudinal profiling identified sex-specific immune trajectories and symptom associations.

Does not show: Observed trajectories do not manipulate the mediator; the linked preprint is not independent evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID38948732. Subclaims: SC1, SC2, SC3.

[36] Autoantibodies against SUMO1-DHX35 in long-COVID.

Shows: Selected female patients had SUMO1-DHX35 antibody findings and antigen assays.

Does not show: Small subgroup and binding assays do not demonstrate antibody pathogenicity or syndrome-wide primacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[37] Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome.

Shows: Salivary antibody patterns were consistent with altered herpesvirus/HERV-related responses.

Does not show: Antibodies are indirect reactivation proxies and are not proof of a SARS-CoV-2 reservoir cause.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[38] The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China.

Shows: Tissue RNA detection in a Chinese cohort was associated with Long-COVID symptoms.

Does not show: Selected biopsies, cross-sectional measurement and reverse causation remain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[39] Persistent complement dysregulation with signs of thromboinflammation in active Long Covid.

Shows: Longitudinal proteomics linked complement/thromboimmune abnormalities to Long COVID.

Does not show: Prediction and pathway enrichment are not pathway-specific human intervention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[40] Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2.

Shows: Persistent Long COVID showed T/B-cell coordination abnormalities.

Does not show: Association does not prove antigen dependence; the linked preprint is not a separate study.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID36798286. Subclaims: SC1, SC2, SC3.

[41] Long COVID involves activation of proinflammatory and immune exhaustion pathways.

Shows: Two-cohort profiling found persistent immune exhaustion-related changes.

Does not show: An attached erratum and noninterventional design limit mechanistic attribution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID41578033. Subclaims: SC1, SC2, SC3.

[42] Seasonal Coronavirus-Induced Immunological Imprinting and Previous Herpesvirus Infections in Patients With Long COVID.

Shows: Antibody patterns suggested seasonal-coronavirus imprinting and herpesvirus-related responses.

Does not show: Cross-sectional immune history cannot identify the dominant maintenance mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[43] Increased anti-nucleocapsid secretory IgA and consumption of complement component 3 in post-COVID syndrome patients.

Shows: Salivary anti-nucleocapsid IgA and complement measurements supported a candidate diagnostic pattern.

Does not show: Diagnostic discrimination is not causal dependency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[44] Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome.

Shows: Post-COVID participants had persistent autoimmune/effector-cell profiles.

Does not show: Presence does not establish immune-pathway or viral-reservoir primacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[45] Small Fiber Neuropathy in Long COVID: A Cohort Study with Multimodal Assessment and Follow-Up.

Shows: Selected patients with autonomic complaints had small-fiber biopsy abnormalities.

Does not show: Small selected case series without a viral or neural intervention cannot determine causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[46] Autonomic dysfunction and vasoregulation in long COVID-19 are linked to anti-GPCR autoantibodies.

Shows: GPCR antibodies associated with vascular regulation measures but lacked the tested cardiomyocyte beating effect.

Does not show: One negative functional assay does not exclude all antibody effects, while association alone does not establish them.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[47] Post-COVID exercise intolerance is associated with capillary alterations and immune dysregulations in skeletal muscles.

Shows: Long-COVID muscle biopsies showed immune/microvascular changes without detected muscle SARS-CoV-2 RNA.

Does not show: Historical controls and a sampled tissue's negative assay do not establish whole-body viral clearance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[48] Muscle abnormalities worsen after post-exertional malaise in long COVID.

Shows: Exercise provocation revealed postexertional muscle injury and metabolic dysfunction.

Does not show: Provoked downstream injury does not identify a viral maintenance mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[49] A causal link between autoantibodies and neurological symptoms in long COVID.

Shows: Transfer of patient IgG caused selected fatigue/pain/nerve phenotypes in mice.

Does not show: Passive transfer supports model pathogenic potential, not endogenous human necessity or a single cause across Long COVID.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID38947091. Subclaims: SC1, SC2, SC3.

[50] Autoimmunity is a hallmark of post-COVID syndrome.

Shows: Autoantibody findings were common in a selected post-COVID cohort.

Does not show: Prevalence and binding do not establish pathogenic function; related commentary is not additional evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[51] The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19.

Shows: Post-acute cytokine changes were associated with persistent sequelae without a corresponding autoantibody pattern.

Does not show: Immune heterogeneity does not identify a universal mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[52] Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms.

Shows: Persistent antinuclear antibody titers tracked selected symptom trajectories.

Does not show: Longitudinal association does not establish necessity or primary direction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[53] Functional Autoantibodies Targeting G-Protein-Coupled Receptors and Their Clinical Phenotype in Patients with Long-COVID.

Shows: A selected cohort showed functional GPCR-antibody bioassay signals associated with symptoms.

Does not show: Assay specificity and lack of adequate causal controls constrain human mechanism inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[54] Age-related transcript changes in type I interferon signaling in children and adolescents with long COVID.

Shows: Pediatric post-COVID interferon-related transcription differed across age strata.

Does not show: Age-opposed patterns caution against a single invariant immune state; no mediator intervention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[55] Single-Cell and Plasma Proteomics Do Not Differentiate Patients With and Without SARS-CoV-2 Antigenemia in Convalescence in a Cohort of 100 Patients.

Shows: Persistent antigenemia was not accompanied by the measured broad immune-proteomic differences.

Does not show: A blood null does not exclude compartmental tissue effects or prove all antigen biologically inert.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[56] Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae.

Shows: Persistent circulating spike was reported preferentially in the sampled PASC group.

Does not show: Circulating antigen association does not establish infectious replication or symptom necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• long-covid-viral-persistence.review.md
• long-covid-viral-persistence.scorecard.json
• reader-summary.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 56 · load-bearing claims: 60 · verified: 60 · unverified: 0 · contradicted: 0 · schema 5.3